Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Despite the Pentagon adding WuXi AppTec to a list of entities allegedly linked to China's military, analysts predict minimal disruption to collaborations between multinational drug makers and Chinese biopharmaceutical firms. The primary driver for continued engagement remains China's significant cost advantages in manufacturing.

Cui Cui, head of healthcare research for Asia at Jefferies, stated that multinational companies still prefer "made-in-China" for cost efficiency, ensuring WuXi AppTec's earnings visibility remains intact. The global pharmaceutical industry faces mounting pressure from drug pricing reforms and upcoming patent expirations for blockbuster drugs. This environment makes cost flexibility a key competitive edge, which China's biopharmaceutical sector currently offers.

The US Department of Defense updated its Section 1260H list to include 188 entities, up from 134, with WuXi AppTec being a new addition in the healthcare sector. This follows previous attempts by the US government to target Chinese life-sciences companies. For instance, the BioSecure Act initially named five Chinese firms, including WuXi AppTec, but all were removed before the bill was signed into law in December.

Industry players suggest that political headwinds are unlikely to halt healthcare collaboration. The persistent drive to improve patient outcomes and reduce healthcare costs is expected to ultimately prevail over geopolitical concerns. WuXi AppTec's shares experienced a notable drop on Tuesday following the announcement but showed signs of recovery.

“

We view minimal impact given multinational [companies] in pharma still prefer made-in-China for cost efficiency. Meanwhile, Wuxi AppTec earnings visibility remains intact.